400 mg/100 mg film-coated tablets
- Antiviral for systemic use. Direct acting antivirals.
- VELPANAT is an oral fixed-dose combination of sofosbuvir, a pan-genotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication and velapatasvir, an HCV inhibitor targeting the HCV NS5A protein, which is essential for both RNA replication and the assembly of HCV virions.
- VELPANAT is indicated for the treatment of chronic hepatitis C (CHC).
- Sofosbuvir/velpatasvir is the first available pangenotypic NS5A-NS5B inhibitor single-pill combination regimen and is highly efficacious across HCV genotypes 1 to 6.